Sophiris Bio (SPHS) Given “Buy” Rating at Maxim Group

Maxim Group restated their buy rating on shares of Sophiris Bio (NASDAQ:SPHS) in a report issued on Wednesday morning. They currently have a $5.00 price target on the biopharmaceutical company’s stock, down from their prior price target of $6.00.

Several other analysts have also recently weighed in on SPHS. HC Wainwright restated a buy rating and set a $6.00 price target on shares of Sophiris Bio in a report on Friday, November 10th. ValuEngine upgraded Sophiris Bio from a strong sell rating to a sell rating in a report on Friday, December 15th. One equities research analyst has rated the stock with a sell rating and four have issued a buy rating to the company’s stock. The company presently has a consensus rating of Buy and an average price target of $6.00.

Shares of Sophiris Bio (SPHS) opened at $2.02 on Wednesday. The company has a current ratio of 13.37, a quick ratio of 13.37 and a debt-to-equity ratio of 0.60. Sophiris Bio has a twelve month low of $1.80 and a twelve month high of $2.95.

Large investors have recently added to or reduced their stakes in the company. Vanguard Group Inc. grew its holdings in shares of Sophiris Bio by 1.0% during the second quarter. Vanguard Group Inc. now owns 731,437 shares of the biopharmaceutical company’s stock worth $1,609,000 after purchasing an additional 7,600 shares during the last quarter. Millennium Management LLC bought a new stake in Sophiris Bio in the fourth quarter valued at approximately $453,000. Goldman Sachs Group Inc. bought a new stake in Sophiris Bio in the fourth quarter valued at approximately $312,000. Finally, Virtu Financial LLC boosted its holdings in Sophiris Bio by 389.7% in the fourth quarter. Virtu Financial LLC now owns 169,790 shares of the biopharmaceutical company’s stock valued at $385,000 after acquiring an additional 135,119 shares during the last quarter. Institutional investors own 5.52% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This article was first published by Week Herald and is owned by of Week Herald. If you are reading this article on another website, it was illegally stolen and reposted in violation of international trademark & copyright laws. The legal version of this article can be accessed at https://weekherald.com/2018/02/15/sophiris-bio-sphs-given-buy-rating-at-maxim-group.html.

About Sophiris Bio

Sophiris Bio, Inc, formerly Protox Therapeutics Inc, is a Canada-based biopharmaceutical company focused on the research, development and commercialization of products for the treatment of urological diseases. The Company has operations based in San Diego developing a treatment for benign prostatic hyperplasia (benign prostatic hyperplasia (BPH) or enlarged prostate).

Receive News & Ratings for Sophiris Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sophiris Bio and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply